Tonix Pharmaceuticals Will Present At The Noble Financial Annual Investor Conference

Tonix Pharmaceuticals Will Present At The Noble Financial Annual Investor Conference

shutterstock_163229570Tonix Pharmaceuticals Holding Corp will be presenting at the Eleventh Annual Noble Financial Capital Markets Investor Conference that will take place in Sandpiper Bay, FL. The company’s CEO and president, Seth Lederman, will be delivering a corporate overview on Tuesday, January 20 at 3:30 p.m. ET.

The presentation will be webcast live and accessed through the Events tab of the Investor Relations page on the company’s official website at www.tonixpharma.com. The presentation will be available for 60 days, according to a press release.

Tonix Pharmaceuticals is a clinical-stage company developing medicines for common disorders of the central nervous system such as episodic tension-type headache, post-traumatic stress disorder (PTSD) and fibromyalgia. These disorders are characterized by chronic disability, and patients suffering with these conditions have no viable treatment options. The diseases cause a significant economic burden to societies since there is a high rate of utilization of the healthcare services by these patients.

Tonix Pharmaceuticals’ candidate TNX-102 SL is the company’s first-line treatment for PTSD and fibromyalgia. It has recently begun a Phase 2 study in PTSD and a new Phase 3 project in fibromyalgia will begin in the next quarter of the year. In addition, a Phase 2 trial of TNX-201 to address episodic tension-type headache will be started around the same time.

The company recently received written guidance from the United States Food and Drug Administration (FDA) on the Phase 3 clinical trials for TNX-102 SL as a treatment for fibromyalgia.

Fibromyalgia is chronic condition characterized by widespread pain and allodynia (pain caused by a stimulus). The symptoms related to the disease are fatigue, joint stiffness and sleep disturbance, tingling, problems with swallowing and some cognitive dysfunction (the symptoms vary from patient to patient).

“Getting this confirmation from the FDA – particularly its acceptance of the 30 percent responder analysis as the primary outcome measure — represents a clear step forward in our ongoing development of TNX-102 SL in fibromyalgia. (…) Our proposed Phase 3 study design is based on our analysis and learnings from the BESTFIT trial results. We are on track to begin the Phase 3 clinical study in this debilitating condition in the second quarter of this year,” said Seth Lederman, president of Tonix Pharmaceuticals, in a press release.

Leave a Comment

Your email address will not be published. Required fields are marked *